iPS cell-based induced nephron progenitor cells (Sumitomo Dainippon Pharma/Jikei University/Bios/PorMedTec)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameiPS cell-based induced nephron progenitor cells (Sumitomo Dainippon Pharma/Jikei University/Bios/PorMedTec)
Drug Alias Namerenal regenerative therapy (Sumitomo Dainippon Pharma/Jikei University/Bios/PorMedTec)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Kidney stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRenal Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorth AmericaJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJikei University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBios Co LtdPorMedTec Co LtdJikei University +[4] 
Active IndicationsN/A
Inactive IndicationsRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A